HPV vaccine: MedImmune/GlaxoSmithKline

Current Opinion in Investigational Drugs

Volumn 4, Issue 2, 2003, Pages 210-213

  Billich, Andreas ^a  

^a Novartis Research Institute   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MEDI 501; MEDI 503; MEDI 504; MEDI 517; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONDYLOMA; DOSE CALCULATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION PAIN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; UTERINE CERVIX CANCER; VACCINATION; VIRUS PARTICLE; WART VIRUS;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL VACCINES;

EID: 0037305131     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. 189175 MedImmune acquires exclusive license to human papillomavirus vaccine technology from University of Rochester. MedImmune Inc Press Release 1995 October 05
2. 212925 MedImmune in-licenses key human papillomavirus vaccine intellectual property from German cancer research center. MedImmune Inc Press Release 1996 June 26
3. 232178 MedImmune begins clinical trial with the first preventative human papillomavirus vaccine candidate. MedImmune Press Release 1997 February 03
4. 272068 MedImmune and SmithKline Beecham form worldwide human papillomavirus vaccine alliance. MedImmune Inc Press Release 1997 December 11
5. 275041 MedImmune finalizes vaccine agreement with SmithKline Beecham. MedImmune Inc Press Release 1998 January 16
6. 299654 New data from MedImmune clinical trials presented at ICAAC - Results from trials evaluating HPV vaccine and Synagis for treatment of RSV. MedImmune Inc Press Release 1998 September 28
7. 304766 Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, Hurni WM, Joyce JG, Lehman ED, Markus HZ, Neeper MP et al J Infect Dis 1997 176 5 1141-1145
8. 318665 In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA J Virol 1998 72 2 959-964 This paper describes HPV-16 virion neutralization with antibodies induced by L1 VLPs of the same virus type; neutralization is type-restricted.
9. 318696 Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R Proc Natl Acad Sci USA 1995 92 25 11553-11557 This paper provides proof-of-principples of protective anti-HPV immunization in a canine animal model.
10. 352634 MedImmune ethyol, neutrexin sNDA trials to be concluded in 2000. FDC Reports Pink Sheet 2000 62 2 24
11. 394715 GlaxoSmithKline plc: Commencement of dealings, GlaxoSmithKline Plc Press Release 2000 December 27
12. 425924 Synagis re-treatment patients represent 21% of use, MedImmune says. FDC Reports Pink Sheet 2001 63 42 24-25
13. 426984 MedImmune licenses cancer target from Purdue Research Foundation. MedImmune Inc Press Release 2001 October 25
14. 427159 Xenova Group plc: Successful results of phase IIa and phase I HPV-related clinical trials and start of combined 'prime-boost' phase II trial. Xenova Group Plc Press Release 2001 October 26
15. 439436 Human papillomavirus vaccines. Stanley MA Curr Opin Mol Ther 2002 4 1 15-22
16. 467734 Product development pipeline - October 2002. GlaxoSmithKline Plc Company Publication 2002 October 23
17. 473835 R&D pipeline. MedImmune Inc Company World Wide Web Site 2002 November 25
18. 474255 Cervical cancer vaccines: Emerging concepts and developments. Da Silva DM, Eiben GL, Fausch SC, Wakabayashi MT, Rudolf MP, Velders MP, Kast WM J Cell Physiol 2001 186 2 169-182
19. 474256 Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS Virology 1996 219 1 37-44
20. 474257 Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, TrinDinh-Desmarquet C, Orth G, Schiller JT, Lowy DR J Virol 1995 69 6 3959-3963
21. 474259 Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment. Cornelison TL Curr Opin Oncol 2000 12 5 466-473
22. 474265 Drug development pipeline. MedImmune Inc Company World Wide Web Site 2002 December 17
23. 474266 Progress in the development of human papillomavirus vaccines for HPV-11 and HPV-16/18 and mapping of a critical neutralizing epitope. Balsley JF, Connor EM, Reichman RC, Dubin G, Strouse RJ, Suzich JA, Koenig S 18th Int Papillomavirus Conf 2000 Abs 366
24. 474935 News headlines. Merck & Co Inc Company World Wide Web Site 2002 December 24 Website announces that HPV virus-like particle vaccine successfully stimulates specific humoral and cellular immune responses.
25. 474937 Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. Balmelli C, Roden R, Potts A, Schiller J, Grandi P, Nardelli-Haefliger D J Virol 1998 72 10 8220-8229
26. 474953 Clinical trials. NIH Company World Wide Web Site 2002 December 24 Website describes vaccine therapy in treating patients with recurrent or persistent cervical cancer.
27. 476563 Medimmune - Presentation at the JP Morgan H&Q 21st Annual Healthcare Conference. MedImmune Inc Company Presentation January 06
28. 477603 United States Biotechnology: MedImmune Inc. Merrill Lynch Co 2002 October 24